Objective: To examine the cost-effectiveness of a newly approved combination of bempedoic acid and ezetimibe (BAEze) in patients with ASCVD from a U.S. healthcare sector perspective. Methods: State-transition Markov model of US adults with ASCVD and low-density lipoprotein cholesterol (LDL-C) ...
1 基本信息 Bempedoic Acid 的化学名为 8-羟基-2,2,14, 14⁃四甲基十五烷二酸,分子式为 C19H36O5,相对分子 质量为 344. 5,其化学结构式见图 1. HO 代动力学特征,ESP15228 对 Bempedoic Acid 总体临 床活性的贡献可能较小.Bempedoic Acid 的表观分 布容积(Vd/F)为 18 L,Bempedoic Acid 原型药物...
Bempedoic acid for high-risk patients with CVD as adjunct lipid-lowering therapy: a cost-effectiveness analysis J Clin Lipidol, 14 (2020), 10.1016/j.jacl.2020.08.013 772–83 Google Scholar [56] U. Laufs, M. Banach, G.B.J. Mancini, D. Gaudet, L.T. Bloedon, L.R. Sterling, et ...
Bempedoic Acid (BA) is a novel Lipid-Lowering Therapy (LLT). We performed a systematic review and meta-analysis to assess the efficacy and safety of BA in patients with hypercholesterolemia. PubMed, Scopus, and Cochrane library databases were searched fo
Bempedoic Acid Capsules Bempedoic Acid Injectable The ” Pharma Grade Bempedoic Acid Market” is mainly divided into product categories, with an emphasis on the different forms that bempedoic acid comes in for medical application. The effectiveness of bempedoic acid, a particular lipid-lowering drug, ...
Bempedoic acidCost-effectivenessCardiovascular diseaseLipid-loweringPreventionBACKGROUND: Bempedoic acid is a novel adenosine triphosphate citrate lyase inhibitor shown to reduce low density lipoprotein cholesterol when used as an adjunct lipid-lowering therapy in patients with high cardiovascular disease (CVD)...
Outcomes of interest were the incremental cost-effectiveness ratios (ICERs) in terms of cost per quality-adjusted life year (QALY) gained and cost per year of life saved (YoLS). Outcomes were discounted at 5% per annum. Results Among 1000 individuals, bempedoic acid in addition to statin ...
Background Low-density lipoprotein cholesterol (LDL-C) has an established role in the development of atherosclerotic cardiovascular disease. The 2019 ESC/EAS dyslipidaemia guidelines recommended more intensive treatment goals, however, many patients do not reach them. Bempedoic acid (BA) is a first-...
Abstract 4131775: Effectiveness of Lipid-lowering therapy with Bempedoic Acid plus Ezetimibe in a Real-world CohortHypercholesterolemiaHyperlipidemiaIntroduction: Bempedoic acid and the combination with ezetimibe (BA+EZE) have demonstrated low-density lipoprotein cholesterol (LDL-C) lowering in clinical trials...
725 Cost Effectiveness of Bempedoic Acid for Those at High Risk Cardiovascular Diseasedoi:10.1016/j.hlc.2020.09.732K. PereraN. KamZ. AdemiD. LiewE. ZomerHeart, Lung and Circulation